市場調查報告書

脂肪萎縮症(LS)市場 - 市場考察,流行病學,市場預測 ∼2027年

Lipodystrophy Syndrome (LS) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 751747
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
脂肪萎縮症(LS)市場 - 市場考察,流行病學,市場預測 ∼2027年 Lipodystrophy Syndrome (LS) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

本報告提供全球脂肪萎縮症(LS)市場調查,彙整疾病概要,各國流行病學,患病數·診斷數的變化與預測,已上市治療藥及新藥概要,各國市場規模,市場成長要素及障礙分析等相關資訊。

目錄

第1章 簡介

第2章 市場概要

  • 主要7個國家的市場規模(實際成果值)
  • 主要7個國家的市場規模(預測值)

第3章 疾病背景和概要

  • 簡介
  • 原因
  • 病理生理學
  • 症狀
  • 風險因素
  • 診斷

第4章 脂肪萎縮症(LS):流行病學和患者人口

  • 主要7個國家的患病數
  • 主要7個國家的患病數:各類型
  • 主要7個國家的診斷數及可治療的病例數

第5章 脂肪萎縮症(LS):各國流行病學

  • 美國
    • 患病數
    • 患病數:各類型
    • 診斷數及可治療的病例數
  • 歐盟5國
    • 德國
      • 患病數
      • 患病數:各類型
      • 診斷數及可治療的病例數
    • 法國
      • 患病數
      • 患病數:各類型
      • 診斷數及可治療的病例數
    • 義大利
      • 患病數
      • 患病數:各類型
      • 診斷數及可治療的病例數
    • 西班牙
      • 患病數
      • 患病數:各類型
      • 診斷數及可治療的病例數
    • 英國
      • 患病數
      • 患病數:各類型
      • 診斷數及可治療的病例數
  • 日本
    • 患病數
    • 患病數:各類型
    • 診斷數及可治療的病例數

第6章 治療方法

  • 治療流程
  • 治療指南

第7章 已上市的治療藥

  • Myalept:Bristol-Myers Squibb
  • 作用機制
  • 法規的里程碑
  • 優點與缺點
  • 安全性和有效性
  • 產品的簡介

第8章 新藥

  • 關鍵交叉競爭
    • Volanesorsen:Ionis Pharmaceuticals
    • Lipaglyn:Zydus Cadila

第9章 脂肪萎縮症(LS)的市場規模

  • 主要的觀察
  • 主要7個國家的脂肪萎縮症(LS)市場分析
    • 脂肪萎縮症(LS)市場概要
    • 脂肪萎縮症(LS)的市場規模

第10章 市場分析:各國主要7個國家

  • 美國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 英國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 整體市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 整體市場規模
    • 市場規模:各治療藥物
  • 日本
    • 整體市場規模
    • 市場規模:各治療藥物

第11章 市場成長要素

第12章 市場障礙

第13章 調查方法

  • 利用之資訊來源

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0483

DelveInsight's "Lipodystrophy Syndrome (LS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Lipodystrophy Syndrome (LS), historical and forecasted epidemiology as well as the Lipodystrophy Syndrome (LS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Lipodystrophy Syndrome (LS) market report provides current treatment practices, emerging drugs, Lipodystrophy Syndrome (LS) market share of the individual therapies, current and forecasted Lipodystrophy Syndrome (LS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Lipodystrophy Syndrome (LS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Lipodystrophy Syndrome (LS) Disease Understanding and Treatment Algorithm

The DelveInsight Lipodystrophy Syndrome (LS) market report gives a thorough understanding of the Lipodystrophy Syndrome (LS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Lipodystrophy Syndrome (LS).

Treatment

It covers the details of conventional and current medical therapies available in the Lipodystrophy Syndrome (LS) market for the treatment of the condition. It also provides Lipodystrophy Syndrome (LS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Lipodystrophy Syndrome (LS) Epidemiology

The Lipodystrophy Syndrome (LS) epidemiology division provide insights about historical and current Lipodystrophy Syndrome (LS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Lipodystrophy Syndrome (LS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Lipodystrophy Syndrome (LS) Epidemiology

The epidemiology segment also provides the Lipodystrophy Syndrome (LS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Lipodystrophy Syndrome (LS) Drug Chapters

Drug chapter segment of the Lipodystrophy Syndrome (LS) report encloses the detailed analysis of Lipodystrophy Syndrome (LS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Lipodystrophy Syndrome (LS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Lipodystrophy Syndrome (LS) treatment.

Lipodystrophy Syndrome (LS) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Lipodystrophy Syndrome (LS) treatment.

Lipodystrophy Syndrome (LS) Market Outlook

The Lipodystrophy Syndrome (LS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Lipodystrophy Syndrome (LS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Lipodystrophy Syndrome (LS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Lipodystrophy Syndrome (LS) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Lipodystrophy Syndrome (LS) market in 7MM.

The United States Market Outlook

This section provides the total Lipodystrophy Syndrome (LS) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Lipodystrophy Syndrome (LS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Lipodystrophy Syndrome (LS) market size and market size by therapies in Japan is also mentioned.

Lipodystrophy Syndrome (LS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Lipodystrophy Syndrome (LS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Lipodystrophy Syndrome (LS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lipodystrophy Syndrome (LS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Lipodystrophy Syndrome (LS) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Lipodystrophy Syndrome (LS) emerging therapies.

Reimbursement Scenario in Lipodystrophy Syndrome (LS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Lipodystrophy Syndrome (LS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Lipodystrophy Syndrome (LS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Lipodystrophy Syndrome (LS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Lipodystrophy Syndrome (LS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Lipodystrophy Syndrome (LS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Lipodystrophy Syndrome (LS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Lipodystrophy Syndrome (LS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lipodystrophy Syndrome (LS) market

Report Highlights

  • In the coming years, Lipodystrophy Syndrome (LS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lipodystrophy Syndrome (LS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Lipodystrophy Syndrome (LS). Launch of emerging therapies will significantly impact the Lipodystrophy Syndrome (LS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lipodystrophy Syndrome (LS)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Lipodystrophy Syndrome (LS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Lipodystrophy Syndrome (LS) Pipeline Analysis
  • Lipodystrophy Syndrome (LS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Lipodystrophy Syndrome (LS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Lipodystrophy Syndrome (LS) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Lipodystrophy Syndrome (LS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Lipodystrophy Syndrome (LS) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Lipodystrophy Syndrome (LS) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Lipodystrophy Syndrome (LS) market size during the forecast period (2017-2030)?
  • At what CAGR, the Lipodystrophy Syndrome (LS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Lipodystrophy Syndrome (LS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Lipodystrophy Syndrome (LS) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Lipodystrophy Syndrome (LS)?
  • What is the historical Lipodystrophy Syndrome (LS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Lipodystrophy Syndrome (LS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Lipodystrophy Syndrome (LS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Lipodystrophy Syndrome (LS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Lipodystrophy Syndrome (LS) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Lipodystrophy Syndrome (LS) in the USA, Europe, and Japan?
  • What are the Lipodystrophy Syndrome (LS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Lipodystrophy Syndrome (LS)?
  • How many therapies are developed by each company for Lipodystrophy Syndrome (LS) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Lipodystrophy Syndrome (LS) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Lipodystrophy Syndrome (LS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lipodystrophy Syndrome (LS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Lipodystrophy Syndrome (LS)?
  • What are the global historical and forecasted market of Lipodystrophy Syndrome (LS)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Lipodystrophy Syndrome (LS) market
  • To understand the future market competition in the Lipodystrophy Syndrome (LS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Lipodystrophy Syndrome (LS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Lipodystrophy Syndrome (LS) market
  • To understand the future market competition in the Lipodystrophy Syndrome (LS) market

Table of Contents

1. Key Insights

2. Executive Summary of Lipodystrophy Syndrome (LS)

3. Competitive Intelligence Analysis for Lipodystrophy Syndrome (LS)

4. Lipodystrophy Syndrome (LS): Market Overview at a Glance

  • 4.1. Lipodystrophy Syndrome (LS) Total Market Share (%) Distribution in 2017
  • 4.2. Lipodystrophy Syndrome (LS) Total Market Share (%) Distribution in 2030

5. Lipodystrophy Syndrome (LS): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Lipodystrophy Syndrome (LS) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Lipodystrophy Syndrome (LS) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Lipodystrophy Syndrome (LS) Treatment and Management
  • 8.2. Lipodystrophy Syndrome (LS) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Lipodystrophy Syndrome (LS) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Lipodystrophy Syndrome (LS): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Lipodystrophy Syndrome (LS) Market Size in 7MM
  • 13.3. Lipodystrophy Syndrome (LS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Lipodystrophy Syndrome (LS) Total Market Size in the United States
    • 15.1.2. Lipodystrophy Syndrome (LS) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Lipodystrophy Syndrome (LS) Total Market Size in Germany
    • 15.3.2. Lipodystrophy Syndrome (LS) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Lipodystrophy Syndrome (LS) Total Market Size in France
    • 15.4.2. Lipodystrophy Syndrome (LS) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Lipodystrophy Syndrome (LS) Total Market Size in Italy
    • 15.5.2. Lipodystrophy Syndrome (LS) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Lipodystrophy Syndrome (LS) Total Market Size in Spain
    • 15.6.2. Lipodystrophy Syndrome (LS) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Lipodystrophy Syndrome (LS) Total Market Size in the United Kingdom
    • 15.7.2. Lipodystrophy Syndrome (LS) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Lipodystrophy Syndrome (LS) Total Market Size in Japan
    • 15.8.3. Lipodystrophy Syndrome (LS) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Lipodystrophy Syndrome (LS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Lipodystrophy Syndrome (LS) Epidemiology (2017-2030)
  • Table 2 : 7MM Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Lipodystrophy Syndrome (LS) Epidemiology in Germany (2017-2030)
  • Table 6 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Lipodystrophy Syndrome (LS) Epidemiology in France (2017-2030)
  • Table 8 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Lipodystrophy Syndrome (LS) Epidemiology in Italy (2017-2030)
  • Table 10 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Lipodystrophy Syndrome (LS) Epidemiology in Spain (2017-2030)
  • Table 12 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Lipodystrophy Syndrome (LS) Epidemiology in the UK (2017-2030)
  • Table 14 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Lipodystrophy Syndrome (LS) Epidemiology in Japan (2017-2030)
  • Table 16 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Lipodystrophy Syndrome (LS) Epidemiology (2017-2030)
  • Figure 2 : 7MM Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Lipodystrophy Syndrome (LS) Epidemiology in the United States (2017-2030)
  • Figure 4 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Lipodystrophy Syndrome (LS) Epidemiology in Germany (2017-2030)
  • Figure 6 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Lipodystrophy Syndrome (LS) Epidemiology in France (2017-2030)
  • Figure 8 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Lipodystrophy Syndrome (LS) Epidemiology in Italy (2017-2030)
  • Figure 10 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Lipodystrophy Syndrome (LS) Epidemiology in Spain (2017-2030)
  • Figure 12 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Lipodystrophy Syndrome (LS) Epidemiology in the UK (2017-2030)
  • Figure 14 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Lipodystrophy Syndrome (LS) Epidemiology in Japan (2017-2030)
  • Figure 16 : Lipodystrophy Syndrome (LS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)